Antipodes Partners LTD Seagen Inc. Transaction History

Antipodes Partners LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$191.51 - $216.16 $15.2 Million - $17.2 Million	79,541 Added 14.27%	636,770 $135 Million
Q2 2023 Jul 25, 2023	SELL	$187.64 - $206.25 $6.4 Million - $7.04 Million	-34,113 Reduced 5.77%	557,229 $107 Million
Q1 2023 May 11, 2023	BUY	$127.59 - $203.08 $2.92 Million - $4.65 Million	22,895 Added 4.03%	591,342 $120 Million
Q4 2022 Feb 08, 2023	BUY	$117.37 - $139.17 $18 Million - $21.4 Million	153,439 Added 36.97%	568,447 $73.1 Million
Q3 2022 Nov 10, 2022	BUY	$135.27 - $180.11 $15.8 Million - $21 Million	116,585 Added 39.07%	415,008 $56.8 Million

Q2 2022 Aug 12, 2022	SELL	$108.81 - $179.33 $13.5 Million - $22.2 Million	-124,029 Reduced 29.36%	298,423 $52.8 Million
Q1 2022 Apr 21, 2022	BUY	$119.61 - $157.85 $4.8 Million - $6.33 Million	40,102 Added 10.49%	422,452 $60.9 Million
Q4 2021 Jun 07, 2022	SELL	$142.57 - $190.86 $168 Million - $224 Million	-1,175,071 Reduced 75.45%	382,350 $59.1 Million
Q4 2021 Apr 21, 2022	BUY	$142.57 - $190.86 $163 Million - $218 Million	1,141,044 Added 274.04%	1,557,421 $46.4 Million
Q4 2021 Feb 14, 2022	BUY	$142.57 - $190.86 $15 Million - $20.1 Million	105,189 Added 33.8%	416,377 $56 Million
Q3 2021 Nov 15, 2021	BUY	$142.45 - $169.82 $44.3 Million - $52.8 Million	311,188 New	311,188 $52.8 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Antipodes Partners LTD, based on Form 13F filings with the SEC.

Stay updated on Antipodes Partners LTD with notifications on news.